Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Jameel Hourani
Observed name:
J Hourani
Observed institutions:
Abbott (United States),
Esteve (Spain)
OpenAlex ID:
A5113554081
The Safety and Tolerance of Xanomeline Tartrate in Patients with Alzheimer's Disease
1995
·
John J. Sramek
, Daniel J. Hurley
, et al.
·
The Journal of Clinical Pharmacology
·
55
Safety and tolerability of CI-979 in patients with alzheimer's disease
1995
·
John J. Sramek
, Allen J. Sedman
, et al.
·
Life Sciences
·
31
Initial safety, tolerability pharmacodynamics, and pharmacokinetics of CI-1007 in patients with schizophrenia.
1998
·
J J Sramek
, M A Eldon
, et al.
·
PubMed
·
13
A Bridging Study of Lu 25-109 in Patients With Probable Alzheimer's Disease
1997
·
John J Sramek
, Misser Forrest
, et al.
·
Life Sciences
·
13
NXX-066 in patients with Alzhemer's Disease: A bridging study
1999
·
John J. Sramek
, Jameel Hourani
, et al.
·
Life Sciences
·
11
Establishing the Maximum Tolerated Dose of Lesopitron in Patients With Generalized Anxiety Disorder
1996
·
John J. Sramek
, Anna Fresquet
, et al.
·
Journal of Clinical Psychopharmacology
·
11
A Bioequivalence Study of Brand and Generic Clozapine in Patients with Schizophrenia
1999
·
John J. Sramek
, Ravi Anand
, et al.
·
Clinical Drug Investigation
·
10
Two Rapid-Dose Titrations of Sertindole in Patients With Schizophrenia
1997
·
John J. Sramek
, Randall J. Mack
, et al.
·
Journal of Clinical Psychopharmacology
·
9
A “bridging” (safety/tolerance) study of Besipirdine Hydrochloride in patients with Alzheimer's disease
1995
·
John J. Sramek
, Christopher Viereck
, et al.
·
Life Sciences
·
9
Show more works
View as search
Works count:
9
Citation count:
162
H-index:
9
I10-index:
7
Year
Topic
Type
